Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial

The Lancet Haematology 2026 Open access

Read full text
Authors: Charlotte L B M Korst, Wouter J. Plattel, Elizabeth de Kort, Febe Smits, Alexandra Croockewit, Mark-David Levin, Matthijs Westerman, Okke de Weerdt, Inger S. Nijhof, Jurgen Wegman, Nina Šmit, Christie P M Verkleij
+11 more Tuna Mutis, Kazem Nasserinejad, Ramses Kerstiens, Marjolein van der Klift, Laurens E. Franssen, Maaike E M de Ruijter, Kaz Groen, Ellen van der Spek, W. Roeloffzen, S Zweegman, N van de Donk
DOI: 10.1016/s2352-3026(25)00298-4
Cited by: 3
References: 35

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Cancer Treatment and Pharmacology Lung Cancer Research Studies

Publication details

Journal / source
The Lancet Haematology
Publisher
Elsevier BV
Volume
13
Issue
1
Pages
e30–e40
Publication date
1 January 2026
Language
EN